Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Quantitative Analysis of Scramble control and LncRNA HMRHL siRNA knockdown in chronic myelogenous leukemia (CML) K562 Cell lines transcriptome profile

ABSTRACT: Quantitative Analysis of Scramble control and LncRNA HMRHL siRNA knockdown in chronic myelogenous leukemia (CML) K562 Cell lines transcriptome profile

PROVIDER: PRJNA704657 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR13778667_1.fastq.gz	Fastqsanger.gz
	SRR13778667_2.fastq.gz	Fastqsanger.gz
	SRR13778668_1.fastq.gz	Fastqsanger.gz
	SRR13778668_2.fastq.gz	Fastqsanger.gz
	SRR13778669_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

Quantitative Analysis of Scramble control and LncRNA HMRHL siRNA knockdown in chronic myelogenous leukemia (CML) K562 Cell lines transcriptome profile

Project description:The goals of this study are to compare differentianl gene expression between Scramble control and knockdown of HMRHL in K562 cell lines. Subsequently to determine the cellular pathway and biological process affected most upon HMRHL silencing from NGS-derived K562 cells transcriptome profiling (RNA-seq).

2021-03-01 | GSE167440 | GEO

Transcription profiling of human K562 cells reveals Imatinib and Nilotinib induced molecular changes in Philadelphia chromosome-positive Chronic Myelogenous Leukemia

Project description:Chronic myelogenous leukemia (CML) is a malignant stem cell disease characterized by a reciprocal translocation between chromosome 9 and 22. The selective bcr-abl tyrosine-kinase inhibitor Imatinib has become the therapy of choice for patients with newly diagnosed CML including those previously considered candidates for allogeneic haematopoietic stem cell transplantation. The tyrosine-kinase inhibitor Nilotinib is a derivate of Imatinib with higher potency. To examine the molecular and functional effects of Nilotinib and Imatinib in chronic myelogenous leukemia, we performed gene expression and functional analyses in K562 cells following treatment with the two tyrosine kinase inhibitors. Experiment Overall Design: Affymetrix U133A 2.0 microarrays were used to examine the gene expression profile of K562 cells after in vitro treatment with Imatinib (0.5 ÂµM) or Nilotinib (0.05 ÂµM) for 24 hours. Gene expression data of the treated cells were compared with data of untreated cells.

2010-01-19 | E-GEOD-19567 | biostudies-arrayexpress

Transcriptome profiling of Bmi1 silenced-K562 CML cell line

Project description:The Bmi1 Polycomb protein is involved in the epigenetic repressive control of self renewal and survival of cancer initiating cells. In Chronic Myeloid Leukemia (CML), bmi1 expression increases gradually as the disease progresses from a chronic latent phase to a deadly blast crisis. We developped an inducible shRNA system to silence Bmi1 in the human K562 chronic myeloid leukemia (CML) cell line in order to identify new Bmi1-target genes. Gene profiling was performed on inducible shBmi1-K562 cells incubated without (P3-K562+shBMI1) or with doxycycline for 96h (P4-K562+shBMI1+doxycycline) using HG-U133 Plus2 Affymetrix Arrays.

2015-05-12 | E-GEOD-54262 | biostudies-arrayexpress

Imatinib and Nilotinib induced molecular changes in Philadelphia chromosome-positive Chronic Myelogenous Leukemia

2009-12-19 | GSE19567 | GEO

A novel small-molecule inhibitor of STAT5A/STAT5B with therapeutic potential for prostate cancer and CML

Project description:We assessed the gene expression profiles induced by both genetic and pharmacological knockdown of Stat5a/b in CML cells. Stat5 was suppressed in K562 cells by lentiviral expression of Stat5 shRNA vs. scramble control for 6 days or by treatment of the cells with IST5-002 (5 µM) for 48 h. K562 cells were treated with IST5-002 (5 µM) or vehicle (DMSO) for 48 h. For Stat5 knockdown, K562 cells were infected with Stat5-shRNA lentivirus or scramble-shRNA lentivirus (as control) for 48 h followed by puromycin (2ug/ml) selection for 6 days to enrich for cells expressing Stat5 or scramble shRNA. Each group (vehicle control, IST5-002, scramble-shRNA control and Stat5-shRNA) was prepared in triplicate, and RNA samples from each group were not pooled.

2015-07-01 | E-GEOD-61312 | biostudies-arrayexpress

Expression analysis of C2C12 cells treated with scramble siRNA or siRNA directed against Fndc1

Project description:We transfected C2C12 cells with 100nM of scrambled siRNA scramble and an siRNA directed against Fndc1. Cells were harvested at 48h post-transfection and RNAseq was performed with polyA selection

2024-08-17 | GSE217125 | GEO

Expression analysis of C2C12 cells treated with scramble siRNA or siRNA directed against Brd4

Project description:We transfected C2C12 cells with 100nM of scrambled siRNA scramble and an siRNA directed against Brd4. Cells were harvested at 48h post-transfection and RNAseq was performed with polyA selection

2022-09-28 | GSE141777 | GEO

Role of Gdpd3 in chronic myelogenous leukemia stem cells

Project description:We examined gene expression profiling in long-term chronic myelogenous leukemia (CML) stem cells isolated from Gdpd3+/+ and Gdpd3-/- CML mouse model by RNA sequence.

2020-08-18 | GSE149442 | GEO

Transcription profiling of human myelogenous leukemia K562 cells expressing BASP1

Project description:We have analysed the dynamic between WT1 and BASP1 in the regulation of gene expression in myelogenous leukaemia K562 cells. Our analysis reveals that BASP1 is a significant regulator of WT1 that is recruited to WT1-binding sites and suppresses WT1-mediated transcriptional activation at several WT1 target genes. We found that WT1 and BASP1 can divert the differentiation program of K562 cells to a non-blood cell type following induction by the phorbol ester PMA. Cell lines were generated expressing the BASP1 gene from the vector pcDNA3. Array analysis was performed on 4 conditions: cells expressing BASP1 and controls, in the absence and presence of Phorbol 12-myristate 13-acetate (PMA).

2010-12-18 | E-MEXP-2573 | biostudies-arrayexpress

Human K562 cells transfected with control or ETO2 siRNA

Project description:microRNA profiling of comparing control or ETO2 siRNA-treated human K562 cells Two-condition experiment, K562-control siRNA vs. K562-ETO2 siRNA, Biological replicates: 1, 1 control siRNA, 1 ETO2 siRNA, independently.

2014-10-01 | E-GEOD-51486 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data